Jeffrey Infante, MD, Director of Drug Development at Sarah Cannon, discusses findings of the AM0010 study.
Risk Group Data Raises Questions on Choice of Frontline Therapy in RCC
June 8th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Manojkumar Bupathi, MD, MS, discussed with participants how risk groups affect their choice of first-line treatment in renal cell carcinoma. This is the first of 2 articles based on this event.
Read More
2 Clarke Drive
Cranbury, NJ 08512